{"title":"[Medical Consultations and Neuropsychological Tests].","authors":"Hideharu Karasawa","doi":"10.11477/mf.030126030530050884","DOIUrl":null,"url":null,"abstract":"<p><p>We are now in an era where neurosurgeons play an active role in the treatment of dementia. One of the most effective ways to gather essential clinical information during the initial consultation is through a structured questionnaire. This helps establish a comprehensive picture of the patient's condition, supports differential diagnosis, and aids in assessing disease severity. With the advent of anti-amyloid-beta antibody therapies, it is now possible to offer targeted treatment for certain types of dementia. Eligibility criteria for administration include a Mini Mental State Examination score of 22-30 for Rekenbi<sup>®</sup> and 20-28 for Kesanra<sup>®</sup>, measured within one month prior to treatment initiation. Additionally, patients should have a Clinical Dementia Rating of 0.5 or 1.</p>","PeriodicalId":35984,"journal":{"name":"Neurological Surgery","volume":"53 5","pages":"884-892"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurological Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11477/mf.030126030530050884","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
We are now in an era where neurosurgeons play an active role in the treatment of dementia. One of the most effective ways to gather essential clinical information during the initial consultation is through a structured questionnaire. This helps establish a comprehensive picture of the patient's condition, supports differential diagnosis, and aids in assessing disease severity. With the advent of anti-amyloid-beta antibody therapies, it is now possible to offer targeted treatment for certain types of dementia. Eligibility criteria for administration include a Mini Mental State Examination score of 22-30 for Rekenbi® and 20-28 for Kesanra®, measured within one month prior to treatment initiation. Additionally, patients should have a Clinical Dementia Rating of 0.5 or 1.